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endometrial cancer?Endometrial cancer (EC) is generally considered a curable and/or
controllable disease, based on standard staging surgery [1]. Accord-
ing to the International Federation of Gynecology and Obstetrics
(FIGO), standard staging surgery includes cytology, total hysterec-
tomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph
node dissection, and para-aortic lymph node dissection [2,3]. Stag-
ing information is a crucial factor for outcome after surgery and for
deciding the appropriate adjuvant therapy [4,5]. A favorable prog-
nosis of EC is based on (1) detection at an early stage and treatment
(e.g., a small tumor, tumor limited within the intrauterine cavity or
superﬁcial myometrial invasion, and absence of extrauterine
spreading); and (2) it involves less invasive cell types (i.e., histolog-
ical grades 1 and 2, and endometrioid cell type EC (E-EC) [i.e., type
I]) [6,7].
The conventional approach for standard staging surgery is surgi-
cal exploration through a midline vertical abdominal incision. The
use of minimally invasive surgery (MIS) such as laparoscopy or
ultra-mini laparotomy for managing various kinds of diseases
such as gynecologic malignancies is popular and widespread. Mini-
mally invasive surgery is an attractive option for an optimal surgical
and oncologic outcome [8,9]. There continue to be concerns
regarding the use of MIS to manage surgical illness, especially ma-
lignancies. The potential risks of MIS include a carbon dioxide effect
and dissemination such as port wound metastases resulting from
the exfoliation of tumor cells, and there is a high risk of intraoper-
ative tumor leakage or rupture because of the limitations in tech-
niques and instruments [10]. With recent advances in techniques
and instruments, most concerns have largely disappeared [11,12].
Furthermore, as evidence has gradually accumulated [13], the use
of MIS in the management of gynecologic malignancies, especially
for EC, has similar overall survival and disease-free survival,
compared to conventional exploratory laparotomy. Moreover, the
advantages of MIS include a signiﬁcant reduction in operative
morbidity and a shorter hospital stay.
The study by Chu et al. [14] in this issue of Taiwanese Journal of
Obstetrics and Gynecology, entitled “Comparison of the laparoscopic
versus conventional open method for surgical staging of endome-
trial carcinoma: A 9-year single institution experience” further sup-
ports the feasibility and effectiveness of MIS in the management of
EC. This retrospective cohort study enrolled 151 patients with EC
(i.e., 70 patients for laparoscopic staging surgery and 81 patients
for laparotomy staging surgery) between January 2004 and June
2012. The data showed no signiﬁcant difference in the recurrence
rate between the two procedures (2.9% vs. 2.5%, p ¼ 0.882) duringhttp://dx.doi.org/10.1016/j.tjog.2016.02.001
1028-4559/Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published b
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a 9-year follow-up period. Minimally invasive surgery further pro-
vided a favorable immediate operation outcome because patients
undergoing MIS for their EC had less blood loss (mean amount,
78 mL vs. 248 mL, p < 0.001), and shorter hospital stay (mean
length, 5 days vs.10 days, p ¼ 0.012), compared to conventional lap-
arotomy staging surgery for EC. The aforementioned ﬁndings re-
ﬂected better recovery of patients when they underwent MIS,
although a short-term or long-term severe postoperative severe
morbidity seemed to be similar between the two modalities. In
fact, Dr. Chu’s ﬁnding is not new; it is only in agreement with the
conclusion of the Cochrane Systematic Review [13].
Based on Dr. Chu’s study, it seemed that MIS was awinner in the
current “PK” (i.e., “player killer”) comparison study. However, some
ﬁndings, although not apparent, need attention, which included
the following: (1) the time required to ﬁnish a procedure was
signiﬁcantly longer for MIS than for the laparotomy staging surgery
(mean time, 159 minutes vs. 140 minutes, p ¼ 0.003); and (2) the
number of retrieved pelvic lymph nodes were fewer in MIS than
in laparotomy staging surgery (mean number, 15 nodes vs. 20
nodes, p ¼ 0.002). Furthermore, the uterine size was signiﬁcantly
smaller in the MIS group than in the laparotomy staging surgery
group (mean size, 187 g vs. 288 g, p ¼ 0.003), which indicates
that a selection bias possibly exists in Dr. Chu’s study. Therefore,
it is not a balanced competition. Moreover, the recurrence pattern
seemed to be different between the two modalities. Metastases at
distant sites (e.g., lung) were a typical ﬁnding in patients (n ¼ 2)
who underwent MIS because these both patients were in the MIS
group, whereas none were in the conventional laparotomy staging
surgery group. By contrast, patients treated with laparotomy stag-
ing surgery tended to have a recurrence at the local site.
Recurrence patterns are traditionally brieﬂy separated into local
recurrence and distant metastases or are synchronous at both sites
[2]. Management of a local recurrence is much easier, although
greatly varied. These recurrent tumors at a local site could be
managed by complete tumor excision, radiation therapy, chemo-
therapy (CT), or a combination of any of these, and may be totally
eradicated by appropriate treatment. However, distant metastases
are considered a systemic disease, and in theory it is nearly impos-
sible to clean the tumors without the simultaneous administration
of agents systematically (e.g., CT or hormone therapy [HT]). In addi-
tion, this approach is frequently viewed as palliative treatment.
Furthermore, recurrent EC is relatively resistant to CT and
frequently unresponsive to HT. All ﬁndings suggest that the
outcome of patients with distant metastases was much worsey Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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study failed to show a statistically signiﬁcant difference in
disease-free survival and overall survival between the two groups,
but this factor may be secondary to the rarity of the recurrence rate
in patients with early-stage EC after primary staging surgery,
regardless of whether adjuvant therapy had been applied.
The question (different metastasis pattern after two surgeries-
MIS and exploratory laparotomy) we raised may not be totally
fair. It may be a result of a coincident ﬁnding in Dr. Chu's study.
However, there is no doubt that the recurrent patterns are really
different in their study. We do not know the real causative mecha-
nisms contributing to this difference. We believe that the signiﬁ-
cantly increased intra-abdominal pressure during MIS may
enhance or push tumors into lymphovascular spaces. The funda-
mental differences during dissection and vessel-occlusion proce-
dures may also contribute to the permeation or penetration of
tumors into the lymphovascular space. We always suture and ligate
the vessels, lymphatic drainage system, and tubes in the conven-
tional laparotomy staging surgery, but we often escape this
suture-ligation step when we perform MIS procedures because
we have a powerful and convenient instrument (e.g., bipolar coag-
ulation system) that can easily complete the occlusion procedure
safely and securely [15]. All of these are hypotheses and much
more investigations are needed to test them. Of course, all efforts
are conducted to provide the beneﬁts of survival after treatment.
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